NASDAQ NMS - GLOBAL MARKET · IRD
-2.95% · -$0.1300 · Vol 326.8K
Live · updated 11:55:34 ET
Opus Genetics Inc

Opus Genetics Inc

Biotechnology
$4.28
Card
Relationship Map

Follow $IRD

One email when a member of Congress discloses a trade in it, with the official filing receipt linked.

Free. No account. Unsubscribe in one click.

Follow $IRD by email

Veridion Score

BETAMEDIUM CONF · 6 of 6 factors measuredMethodology
IRD
Opus Genetics Inc
Wed Oct 7 · last completed session · daily score · 18h old
Lower range

Highest qualified requires a score of at least 75 and high confidence, including full factor coverage. Upper range can hold a higher score with lower confidence.

Composite intelligence score across six company factor categories. Missing inputs are excluded from the active factor subset.

40/ 100
Veridion Score
Lower range · MEDIUM confidence · 6 of 6 factors measured
Sovereign · $25/mo
See why this score moved.
  • · Factor breakdown with raw signals
  • · Day-over-day delta + driver
  • · Factor coverage readout
  • · Valuation · hype · market flow
  • · Pro Chart event markers
  • · Score history + alerts
Start Sovereign · $25/mo →
Cancel anytime · or Reserve · $79/mo
Confidence: MEDIUM · 6 of 6 factors measured · Wed Oct 7 · last completed session · daily score · 18h old
Share on X →
Veridion Score History · 90D
Loading score history
AI Analysis
Sovereign

Why is IRD moving today?

Sovereign unlock connects news, insider activity, analyst moves, and live price action.
Loading IRD catalysts
About Opus Genetics Inc
PHARMACEUTICAL PREPARATIONS
Listed since
2020
Employees
28
Country
US

Opus Genetics Inc is a clinical-stage ophthalmic biopharmaceutical company developing therapies to treat patients with inherited retinal diseases (IRDs) and therapies to treat patients with other retinal and refractive disorders. The pipeline includes seven adeno-associated virus (AAV)-based programs, led by OPGx-LCA5 for LCA5-related mutations and OPGx-BEST1 for BEST1-related retinal degeneration, with additional candidates targeting RHO, CNGB1, RDH12, NMNAT1, and MERTK. The company operates in one operating segment, which is the business of developing products related to vision performance and health.

Company website →
Key statistics

Reported fields plus Veridion-computed history. Unsourced tiles are omitted.

Open
$4.41
Day high
$4.46
Day low
$4.25
Previous close
$4.41
52W high
$6.07
-29.49% from high
52W low
$1.74
59% of range
Market cap
$366.9M
EPS
$-1.2911
Beta
0.74
Shares out
83.2M
Volume
326.8K
0.08× rel vol
Avg volume
4.1M
VWAP
$4.33
Price history computed in-house
1W
-5.10%
1M
-1.38%
3M
+9.18%
1Y
+108.78%
YTD
+112.94%
SMA 50 $4.40 · below
SMA 200 $4.02 · above
52W position 59%

IRD overview

Veridion Score
40
Registered · 2026-10-07
6 of 6 factors measured
Latest receipt rows
0
No recent disclosure on file.
13F holders
None on file

Related filings and maps

Relationship mapTrace receipt-backed holders and filings around IRD.Congress trackerSearch the public STOCK Act disclosure ledger.MethodologyReview score inputs, coverage rules, and limitations.
Loading financial statements
Loading IRD Form 4 filings
Public disclosures

Congress activity in IRD

Congress trackerOpen ticker disclosure ledger →

No receipt-qualified filings found.

Federal contracts

IRD contract awards, year to date.

Public federal awards linked to this ticker.

Not disclosed
Refresh interval: 12hSource: Federal contract awards
No federal contracts on file for IRD in this window.
Lobbying spend

IRD lobbying filings, year to date.

Registered lobbying filings matched to Opus Genetics Inc.

Not disclosed
Refresh interval: 12hSource: LDA disclosure filings
No lobbying filings on file for IRD in this window.
Loading news for IRD
Analyst ratings
Sovereign unlock shows live analyst consensus for IRD.
Options
Options data is temporarily unavailable. Changing your plan will not restore the upstream feed.
Weekly Veridion brief

Rating changes, public disclosure activity, methodology notes, and product updates. One email per week. No advertising list resale.